This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

American Academy of Sleep Medicine
June 1st – 5th 2024, Houston, TX
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted.
Narcolepsy
POSTER
The Burden of Living With Narcolepsy: Patient Perspectives From In-Depth Qualitative Interviews
AUTHOR(S)

Michael J. Doane,1 Meaghan O’Connor,2 Miranda Lauher-Charest,2 Laura Tesler Waldman,2 Wilbur P. Williams, III1

Narcolepsy
POSTER
Safety and Pharmacodynamic Effects of the Orexin 2 Receptor Agonist ALKS 2680 in Patients With Narcolepsy Type 1: A First-in-Human Phase 1 Study
AUTHOR(S)

Ron Grunstein,1 Brendon Yee,1 Julia Chapman,1 Angela D’Rozario,1 Craig Hopkinson,2 Jandira Ramos,2 Daniel Smith,2 Sergey Yagoda,2 Bhaskar Rege2

Narcolepsy
POSTER
Vibrance-1: Study Design and Methods for a Phase 2, Randomized, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Narcolepsy Type 1
AUTHOR(S)

David T. Plante,1 Ron Grunstein,2 Giuseppe Plazzi,3 Anne Marie Morse,4 Jandira Ramos,5 Shifang Liu,5 Sergey Yagoda,5 Bhaskar Rege5